Related Experiment Video

Updated: May 11, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

[Correlation between lipoprotein(a) and fibrinogen in elderly patients with coronary heart disease]

Jie Geng1, Shu-tao Chen, Lin Wang

  • 1Department of Cardiology, Tianjin Chest Hospital, Tianjin, China.

Zhonghua Yi Xue Za Zhi
|May 11, 2013
PubMed

Insights

Lipoprotein(a) (Lp(a)) and fibrinogen (Fib) levels increase with coronary heart disease (CHD) severity in older adults. Both Lp(a) and Fib are identified as significant influencing factors for CHD in this population.

Area of Science:

  • Cardiovascular Medicine
  • Biochemistry
  • Geriatrics

Context:

  • Coronary heart disease (CHD) is a leading cause of mortality in the elderly population.
  • Lipoprotein(a) (Lp(a)) and fibrinogen (Fib) are established cardiovascular risk factors.
  • Understanding the specific roles of Lp(a) and Fib in senior CHD patients is crucial for risk stratification.

Purpose:

  • To investigate the association between Lp(a) and Fib levels and the severity of CHD in patients over 65 years old.
  • To examine the interrelationship between Lp(a) and Fib in the context of CHD.
  • To identify Lp(a) and Fib as potential biomarkers for CHD progression in seniors.

Summary:

  • A study of 784 senior patients undergoing coronary angiography revealed increasing Lp(a) levels in males and increasing Fib levels in both males and females with greater CHD severity (more involved coronary branches).
  • A positive correlation was observed between Lp(a) and Fib levels in male patients.
  • Multivariate analysis indicated that both Lp(a) and Fib are significant influencing factors for CHD in this elderly cohort.

Impact:

  • The findings highlight the importance of monitoring Lp(a) and Fib levels in older individuals at risk for or diagnosed with CHD.
  • This research may inform the development of targeted therapeutic strategies to mitigate CHD progression in the senior population.
  • Establishes a stronger link between these biomarkers and CHD severity, particularly in males, aiding in clinical risk assessment.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...